Depression is a frequent side effect of interferon therapy in patients with chronic hepatitis C (CHC). The aim of this study was to identify baseline and on-treatment predictors of depression in CHC patients receiving peginterferon and ribavirin.
INTRODUCTION
Commonly reported psychiatric side effects of interferon therapy include depression, anxiety, and irritability, although mood changes associated with the underlying medical condition can be difficult to discern from the medication effects (1, 2) . Peginterferon and ribavirin combination therapy is associated with a clinically significant depression in 30-50% of patients with chronic hepatitis C (CHC) treated in clinical trials as well as in clinical practice (3, 4) . Using a battery of objective and validated neuropsychological tests, cognitive function did not worsen during peginterferon and ribavirin treatment of CHC patients with advanced fibrosis (5) . However, many CHC patients receiving antiviral therapy complain This is publication number 24 from the HALT-C Trial Group. not only of impaired cognition but also of moderate-to-severe depression, anxiety, and fatigue, as measured by self-report and interviewer-administered questionnaires (5, 6) . As psychiatric side effects are a leading cause of interferon dose reductions or premature discontinuation, further studies regarding the incidence and pathogenesis of interferon-induced mood alterations are warranted.
Selective serotonin reuptake inhibitors (SSRI) can effectively treat and potentially prevent the depression seen in patients receiving interferon (7) (8) (9) (10) . However, the studies reported to date have identified different, and sometimes, conflicting predictors of interferon-induced depression including baseline mood status (10) (11) (12) (13) . Furthermore, the mechanism(s) of interferon-induced depression have not been elucidated, although a few studies have suggested a possible role for changes in the hypothalamic-pituitary adrenal
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(HPA) axis as well as the central catecholamine and serotonin systems (14) (15) (16) (17) . The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial is a prospective multicenter study designed to investigate the potential benefit of maintenance peginterferon in reducing the rate of disease progression in prior interferon nonresponders with advanced fibrosis (18, 19) . During the lead-in phase, all patients received peginterferon alfa-2a and ribavirin for 24 wk, and subjects who remained viremic at week 20 were eligible for randomization to low-dose peginterferon or no treatment. The subjects who had undetectable HCV RNA by polymerase chain reaction (PCR) at week 20 continued in the responder arm of the study to complete 48 wk of antiviral treatment. In this article, the incidence, baseline predictors, and potential biomarkers associated with mood disturbances in 201 HALT-C patients are reported. It was hypothesized that depressive symptoms at baseline would predict depression during antiviral therapy, and that depression scores would positively correlate with plasma cortisol levels and negatively correlate with whole blood serotonin levels.
METHODS
Patient Population and Study Design
The 201 patients enrolled in this ancillary study were recruited from the University of Michigan (UM) and the University of Southern California (USC). The inclusion criteria for the HALT-C trial were detectable serum HCV RNA, a liver biopsy within 12 months of enrollment showing an Ishak fibrosis score of 3-6, and a lack of response to previous interferon treatment. The exclusion criteria included any other co-existent liver disorder, a history of hepatic decompensation, and intolerance to interferon (19) . Additional exclusion criteria were an active use of illicit drugs, ongoing excessive alcohol consumption, a history of suicide attempt or hospitalization for depression within the past 5 yr, and a history of severe or incapacitating psychiatric condition within the past 6 months. A history of major depression that was not severe or incapacitating at enrollment was not considered as an exclusion criterion. All patients provided written informed consent to participate in the HALT-C trial as well as in this ancillary study at UM and USC.
All subjects were treated with peginterferon alfa-2a at a dose of 180 µg per week (Pegasys; Roche Laboratories, Nutley, NJ) and ribavirin in doses of 1.0-1.2 grams per day (Copegus; Roche Laboratories). Serum HCV RNA testing was done using the quantitative COBAS Amplicor HCV Monitor test (Roche Molecular Diagnostics, Branchburg, NJ) with a lower detection limit of 600 IU/mL and the qualitative COBAS Amplicor HCV test (Roche Molecular Diagnostics) with a lower detection limit of 100 IU/mL. Patients who tested HCV RNA negative at week 20 were considered virological responders and continued with combination antiviral therapy for 48 wk in the responder arm of the study. Patients without detectable HCV RNA at week 72 were considered to have a sustained virological response (SVR). Adherence was defined as taking at least 80% of the prescribed peginterferon and ribavirin dose through week 12 and week 20 (20) .
Psychiatric Assessment
The Composite International Diagnostic Interview (CIDI) is a standardized instrument for the assessment of mental health disorders according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria (21) . In this study, the computerized lifetime (LT) version of the CIDI that included depression, anxiety, alcohol, and substance abuse modules was self-administered at baseline (week 0). During antiviral therapy, the 12-month version of the depression module alone was administered at weeks 24, 48, and 72.
The Beck Depression Inventory (BDI)-II, is a 21-item, selfadministered questionnaire designed to screen for depressive symptoms over the previous 2 wk (22) . The BDI was administered at weeks 0 (baseline), 4, 12, 24, 36, 48, 60 , and 72. A score <10 was considered as no depression, 11-14 as minimal, 15-19 as mild, 20-28 as moderate, and >28 as severe depression. A lifetime alcohol consumption was estimated using a modification of the Skinner survey (23) . Years of education were coded by the highest level completed, and occupation was categorized on a scale of 1-6 with 1 = unskilled/farm labor and 6 = professional/technical (24) .
Definition of Depression
Depression at baseline (week 0) was defined as either a BDI ≥11 or fulfilling the DSM-IV criteria for major depression during the previous 12 months on the CIDI. For subjects without baseline depression, interferon-induced depression was defined at each postbaseline time point as a BDI ≥11 or fulfilling DSM-IV criteria for depression via the CIDI. For subjects with baseline depression (i.e., baseline BDI-II ≥11 or CIDI criteria for depression), interferon-induced depression was defined at each postbaseline time point as a BDI score that had increased by 6 points or more compared with baseline. The rationale for this criterion includes prior studies that used a numerical increase in BDI-II scores or other self-rating scales to define interferon-induced depression in subjects with baseline depression (25, 26) . The use of antidepressants such as SSRI's (e.g., fluoxetine) and non-SSRI's (e.g., nortriptyline) was recorded, but was not part of the definition of depression.
Cortisol and Serotonin Assays
In subjects enrolled at UM, fasting morning blood samples were processed immediately and stored at -70
• C. The samples were tested in batches to minimize interassay variability. Plasma cortisol was measured at the UM Hospital Chemistry Laboratory by a chemiluminescent immunoassay on an Advia Centaur analyzer (Bayer Diagnostics, Tarrytown, NY). The coefficient of variation for the cortisol assay varied from 4.3% to 8.0% over the reference range for morning cortisol levels of 7-22 µg/dL (25) . Whole blood serotonin was measured using a high-pressure liquid chromatography method with fluorescence detection (Bioanalytical Systems, West Lafayette, IN) (26) . The dynamic range of the assay was 1-10,000 nM/L, with a coefficient of variation of 3.0%. Samples with low or undetectable whole blood serotonin levels were repeated to verify the results. As platelets are a rich source of serotonin in whole blood, and interferon therapy is known to reduce platelet counts, the whole blood serotonin/platelet ratio was analyzed as a biomarker of whole body serotonin stores.
Data Analyses
A Kaplan-Meier product-moment analysis was used to estimate the cumulative incidence of depression at week 24 and week 48. A Cox-proportional hazard analysis was used to identify baseline predictors associated with depression in both week 24 and week 48 cohorts. In addition, adherence to antiviral medications as well as week 12 virological response (i.e., decline in HCV RNA by >2 log 10 or undetectable) and week 20 virological response (i.e., HCV RNA undetectable) were tested as predictors of depression. The association of each variable with interferon-induced depression was tested alone, and a multivariable model was computed that included all variables with P < 0.15 and controlling for baseline depression. The association between the biological markers and baseline BDI-II scores in the UM patients was evaluated by the Pearson correlation coefficient. The change over time in the biological markers was evaluated using a repeated-measures analysis of variance (ANOVA). The association between the changes in biomarkers and development of interferon-induced depression through weeks 24 and 48 was evaluated using the Cox proportional hazard analysis. All analyses were carried out using the SAS statistical software version 9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Study Population
The baseline characteristics of the 102 subjects enrolled at UM and the 99 subjects enrolled at USC were comparable in all respects except for the proportion of Hispanics, number of HCV genotype 1 patients, and the duration of HCV infection. Therefore, the data from the 201 subjects were grouped together for analysis (Table 1) . At week 24, 185 subjects completed the BDI-II, while the remaining 16 subjects had withdrawn from the HALT-C study (N = 13), the cognitive study (N = 2), or failed to complete the BDI-II (N = 1). Seventy-four of the 201 patients (37%) had undetectable HCV RNA at week 20 and continued in the responder arm of the trial through week 48. The remaining 127 subjects with detectable HCV RNA at week 20 had antiviral therapy discontinued at week 24 and were eligible for the randomized phase of HALT-C.
The baseline features of the 201 HALT-C patients demonstrated a mean age of 50 yr and 71% were male ( Table 1) . The mean baseline BDI-II score was 6.9, with 22% having a score greater than 11, 5.5% having a score ≥20, and 7% meeting the DSM-IV criteria for depression in the previous 12 months. The 51 HALT-C patients (25%) with baseline depression were significantly more likely to be female, nonCaucasian, and have lower educational levels compared with the 150 nondepressed patients (P < 0.05). In addition, the depressed subjects were significantly more likely to be receiving an antidepressant or anxiolytic at week 0. Finally, the whole blood serotonin/platelet levels tended to be lower in the patients with baseline depression (P = 0.10).
Depression Through Week 24
The cumulative incidence of interferon-induced depression in the 201 subjects increased from 2% at week 4 to 6% at week 12 and 22% at week 24 ( Fig. 1) . The use of antidepressant/anxiolytic medications at baseline (P = 0.054) and the failure to achieve a week 12 virological response (P = 0.018) or week 20 virological response (P = 0.0023) were associated with interferon-induced depression ( Table 2) . As the HALT-C study had called for 24 wk of antiviral therapy, and there was a significant interaction between week 12 and week 20 virological response (kappa = 0.60, P < 0.0001), only week 20 virological response and other variables with P < 0.15 were used in the multivariate model. In the multivariable analysis, only the absence of a week 20 virological response remained significantly associated with interferon-induced depression (P = 0.0009).
Among the 150 subjects without baseline depression, the cumulative incidence of depression was 2% at week 4, 7% at week 12, and 21% at week 24 ( Fig. 1) . Similarly, in the 51 subjects who met the criteria for baseline depression, the cumulative incidence of interferon-induced depression was 4% at weeks 4 and 12, and 32% at week 24 ( Fig. 1) . Therefore, the incidence of interferon-induced depression was not significantly different in patients with and without baseline depression (hazard ratio 1.47, 95% confidence interval [CI] 0.79-2.73, P = 0.22).
Depression Through Week 48
Among the 74 subjects who continued on the antiviral therapy through week 48, 64 (86%) had undetectable HCV RNA at week 48, and overall 38 (51%) achieved an SVR at week 72. The actuarial incidence of interferon-induced depression in these subjects increased from 4% at week 4 to 9% at week 24, and 42% at week 48 ( Fig. 2) . However, none of the baseline features including baseline BDI-II scores or adherence to peginterferon or ribavirin were associated with the development of depression through week 48 (data not shown). Among the 66 subjects with available BDI-II scores through week 72, the mean BDI-II scores at week 72 were significantly lower compared with week 24 (4.7 ± 0.7 vs 7.8 ± 0.7, P = 0.0009) and week 48 (4.7 ± 0.7 vs 7.4 ± 0.7, P = 0.0006), demonstrating that interferon-induced depression is reversible.
Changes in Serum Biomarkers
At baseline, plasma cortisol levels ranged from 2.2 to 24.3 µg/dL, with only 2% of the patients having cortisol levels that exceeded the normal range. There was no significant correlation between the baseline cortisol levels and BDI-II scores.
As noted in Figure 3 , plasma cortisol levels decreased slightly by week 4 and then remained stable at week 24, with no significant change over time (P = 0.60). Furthermore, there was no significant association between cortisol levels and the development of interferon-induced depression through week 24 (P = 0.61) or with BDI-II scores through week 24 (data not shown). Prior to antiviral therapy, whole blood serotonin levels ranged from 4 to 2,023 nM/L, while whole blood serotonin levels normalized to platelet count ranged from 0.02 to 8.80 nM/L/10 3 platelets. There were no significant correlations between baseline whole blood or normalized serotonin levels and BDI-II scores (P = 0.59 and P = 0.23, respectively).
The normalized serotonin levels significantly decreased from baseline through week 24 (P < 0.0001) (Fig. 4) . However, neither the changes in normalized serotonin levels nor the whole blood serotonin levels correlated with interferon-induced depression through week 24 or week 48 (P = 0.35 and P = 0.51, respectively). In addition, there was no significant correlation of these biomarker levels with the BDI-II scores (data not shown).
DISCUSSION
Previously published studies of mood states in CHC patients receiving an antiviral therapy have been limited by the small numbers of patients enrolled, the nonstandardized definitions of depression, and the heterogeneity of antiviral treatment regimens used (2, 27, 28) . In this study, 201 CHC patients with advanced fibrosis entering a clinical trial of peginterferon and ribavirin were prospectively assessed for the changes in mood status over time using a series of validated instruments. The BDI-II was selected due to its brevity and established utility in detecting depression in patients with medical conditions (22, 29, 30) . Furthermore, the BDI-II has been used in previous studies of CHC patients and correlated well with mental health professional assessment of mood disorders (31) . The computerized CIDI depression module that is based upon the DSM-IV criteria was also used and previously shown to correlate with interviewer-administered questionnaires (21) . As the CIDI is self-administered, this instrument may also be more likely to detect depression. Overall, 51 (25%) of the HALT-C patients met the criteria for depression before the antiviral therapy, although the depression was graded as mild in most. The high rate of baseline mood disorders may relate to the referral bias, the requirement for previous nonresponse to interferon and advanced fibrosis to enter the HALT-C study, and the prospective characterization of current and lifetime psychopathology. However, other prospective studies have also identified a 20-30% prevalence of mood disorders in CHC patients prior to antiviral therapy (13, 32) The cumulative incidence of interferon-induced depression increased to 23% by week 24, a rate that is similar to what has been reported in other studies ( Fig. 1) (4, 27, 32) . In addition, 16 subjects (8%) had to prematurely discontinue therapy by week 24 due to various adverse events. Furthermore, 33% of the treated patients took less than 80% of the prescribed peginterferon dose through week 20 due to a variety of side effects including neuropsychiatric toxicity. Based upon the studies of interferon therapy in melanoma and CHC patients, subjects with baseline depression were expected to be at an increased risk of interferon-induced depression (10, 13, 33) .
In support of this, the use of antidepressants/anxiolytics at baseline was associated with interferon-induced depression on the univariate analysis (Table 2) . Although expected trends were noted for several other baseline variables (i.e., baseline depression [P = 0.22], age [P = 0.11]), none remained significant in the multivariate analysis. The absence of a significant association of baseline depression with interferon-induced depression may have been due to the better tolerability of peginterferon compared with high-dose standard interferon used in prior studies and the selection of interferon-"tolerant" patients for the HALT-C study (34, 35) . It is also possible that Normalized whole blood serotonin levels through week 24 in 101 HALT-C patients. The y-axis value was determined by dividing the whole blood serotonin level by the platelet count at each time point and is reported as the mean ± standard error. The mean whole blood serotonin/platelet level did significantly decline during antiviral therapy (P < 0.0001) the definition of interferon-induced depression used in the current study differs from that used in prior studies. As mentioned, a validated depressive symptom rating scale (i.e., the BDI-II) and the CIDI were used to define interferon-induced depression. To address potential ceiling effects with the BDI-II, an increase in the BDI-II score of >6 points was required during treatment for subjects with an elevated baseline score which would change the classification of depression from minimal to mild and mild to moderate. In addition, prior studies have suggested that an increase in the BDI-II score of 6 points is clinically significant (25, 26 ). An alternative approach would have been to use a threshold severity construct to define interferon-induced depression (e.g., a BDI-II score >18). Finally, a frequent assessment of patients during antiviral therapy by a mental health professional would be considered the "gold standard" for verifying the presence of a mood disorder. However, this approach was not feasible due to logistical considerations. A significant association between failure to clear HCV RNA by week 20 and developing depression during the antiviral therapy was observed in the current study. A previous study suggested that CHC patients with more severe psychiatric side effects during treatment were more likely to achieve a virological response (36) . However, this association was not found in four other studies that demonstrated a negative relationship between fatigue and response to antiviral therapy (37) (38) (39) (40) . In the current study, there was no significant difference in the BDI-II score at week 4 or week 12 compared with baseline in the week 20 virologic responders versus nonresponders (data not shown). Therefore, the association noted in our study may have been due, in part, to the sharing of HCV RNA test results with patients during the study and the expected negative impact that the knowledge of persistent viremia could have on a patient's mood. Future studies that blind patients to virological test results may better discern the biological effect of interferon on mood versus the knowledge of the treatment response.
The incidence of interferon-induced depression in the subjects who continued beyond 24 wk increased from 9% at week 24 to 42% by week 48 (Fig. 2) . These data suggest that the neuropsychiatric side effects of peginterferon and ribavirin increase over time. Importantly, however, the mean BDI-II scores of subjects returned to pretreatment baseline levels by week 72, demonstrating the reversibility of interferoninduced depression. The lack of a significant association between any of the baseline variables and interferon-induced depression in this subgroup of 74 subjects may, in part, relate to the smaller sample size and the exclusion of nonresponders beyond week 24.
In addition to determining the frequency and severity of interferon-induced depression, the potential mechanism(s) of neuropsychiatric side effects was explored in the current study. Previous studies of short-term interferon therapy have demonstrated dramatic changes in the HPA axis in healthy individuals and CHC patients (14, 41, 42) . Presumably, the induction of fever and systemic side effects by interferon can lead to a marked stress response, with characteristic increases in adrenocorticotropin-releasing hormone (ACTH) and plasma cortisol levels, as previously noted in subjects with endogenous depression (1) . However, studies of prolonged interferon therapy demonstrate the development of a tolerance to this effect (14) . As seen in Figure 3 , no significant changes in plasma cortisol levels were noted over time. In addition, baseline plasma cortisol levels did not significantly correlate with baseline BDI-II scores, and the changes in cortisol levels over time did not track with the appearance of interferon-induced depression or serial BDI-II scores. These data suggest that alterations in the HPA axis as reflected in morning cortisol levels are not associated with interferoninduced depression in CHC patients. However, it remains plausible that more sensitive and specific measurements of subtle changes in the HPA axis such as the ACTH stimulation test or dexamethasone suppression test could have led to different results.
Previous studies have demonstrated that interferon can lead to downregulation of serotonin synthesis in the brain and depletion of serotonin precursors throughout the body (16, 43) . In addition, depletion of whole body serotonin stores via interferon-mediated induction of indoleamine-2,3-dioxygenase activity has been postulated as a potential mechanism of interferon-induced depression (44) . In the current study, whole blood serotonin levels were measured, which include contributions from platelet-derived serotonin. As interferon is known to cause thrombocytopenia via direct effects on the bone marrow, the changes in normalized whole blood serotonin to platelet levels were also investigated. At baseline, a wide range of whole blood serotonin levels were noted, and subjects with baseline depression tended to have lower levels (Table 1) . However, neither baseline whole blood nor normalized serotonin levels were associated with baseline BDI-II scores. Nonetheless, significant changes in normalized whole blood serotonin levels were seen during the antiviral therapy, although the degree of change did not correlate with the occurrence of depression (Fig. 4) nor with the serial changes in the BDI-II scores. The lack of an association between the changes in whole blood serotonin levels and interferon-induced depression may have been due to the discordance between whole blood and intracerebral serotonin levels. In addition, the nonspecific reduction of platelet count in treated patients from interferon effects on the bone marrow may have obscured a relationship. Finally, the use of SSRI's in 17% of the HALT-C patients during the lead-in phase and 15% during the responder arm may have confounded a relationship between these parameters. Therefore, investigation of more sensitive markers of serotonin metabolism such as serotonin gene polymorphisms, serotonin receptor expression in peripheral lymphocytes, and serum peptidases induced by interferon would be worthwhile (43) (44) (45) (46) (47) (48) (49) (50) (51) .
The strengths of the current study include the enrollment of a large number of well-characterized CHC patients at two clinical sites with varying ethnicity, age, and gender. In addition, standardized and objective measures of mood states were used rather than the subjective clinical assessment of a hepatologist. Although a formal assessment of suspected mood disorders by a mental health professional would have been preferred, this was not feasible. Other strengths of the current study include the assessment of mood status within a clinical trial wherein all patients were seen at regular and frequent intervals and standardized rules for antiviral dose reductions were utilized. Nevertheless, the results of this study may not be generalizable to other patients with CHC due to the strict inclusion criteria of the HALT-C trial. In particular, the inclusion of patients who had previously tolerated a course of interferon therapy may have excluded patients at risk for severe neuropsychiatric toxicity. In addition, subjects with severe or recent psychopathology at baseline were excluded from enrollment into this study of long-term peginterferon therapy. Finally, as in any study that uses a self-administered questionnaire, some subjects could have overestimated psychiatric symptoms, while others may have underestimated their symptoms due to questionnaire fatigue. However, the cumulative incidence of interferon-induced depression at weeks 24 and 48 is similar to what has been reported in other studies of mood disorders in CHC patients (36) (37) (38) (39) (40) .
In summary, the cumulative incidence of interferoninduced depression in patients receiving peginterferon and ribavirin enrolled in the HALT-C trial was 23% at week 24 and 42% at week 48. Contrary to initial hypotheses, many pretreatment characteristics were not associated with interferoninduced depression including the baseline depression, liver disease severity, and lifetime psychiatric and alcohol consumption history. However, as expected, receiving an antidepressant or anxiolytic medication at baseline was associated with depression, as was the absence of a virological response at week 12 and week 20. Morning plasma cortisol levels did not change significantly during therapy and were not associated with depression before or during antiviral therapy. In contrast, normalized serotonin levels decreased significantly during antiviral therapy, but were not associated with the development of interferon-induced depression. Additional studies of serotonergic pathways in the pathogenesis of mood disorders during antiviral therapy of CHC are warranted to improve our understanding of the biological basis of this common and dose-limiting side effect of the treatment.
